Finland introduces rotavirus vaccine into the national vaccination programme in September 2009.
Supported by an economic evaluation, rotavirus vaccine is introduced into the national immunisation schedule in Finland. The vaccination programme has been estimated to be reasonably cost-effective. Given at the age of two, three and five months, the vaccine is expected to prevent annually in Finland among children under the age of five years approximately 2,000 rotavirus diarrhoea episodes needing hospitalisation, and over 10,000 outpatient visits. The impact of the programme will be evaluated in 2011 by repeating the economic analysis and carefully monitoring adverse events.
Nohynek
H
H
Department of Vaccines and Immune Protection, National Institute of Health and Welfare, Helsinki, Finland. hanna.nohynek@thl.fi
Salo
H
H
Renko
M
M
Leino
T
T
D003362:Cost-Benefit Analysis; D064420:Drug-Related Side Effects and Adverse Reactions; D005387:Finland; D006801:Humans; D017589:Immunization Programs / Q000191:economics; D015397:Program Evaluation; D012400:Rotavirus Infections / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000627:therapeutic use*
D022243:Rotavirus Vaccines